Mirror Biologics has Initial Clearance for Phase II/III Clinical Trial in Advanced Liver Cancer
Mirror Biologics, Inc. announced the clearance of the “ALIVE” Phase II/III randomized, controlled clinical trial for subjects with advanced, treatment-naïve, Hepatocellular Carcinoma (HCC) by the Malaysia Research Ethics Committee (MREC)…
Continue Reading
Mirror Biologics has Initial Clearance for Phase II/III Clinical Trial in Advanced Liver Cancer